Cardiac Sympathetic Imaging With mIBG in Heart Failure
Cardiac Sympathetic Imaging With mIBG in Heart Failure
复制标题
DOI：
10.1016/j.jcmg.2009.07.014
复制
发表时间：
2010-01-01
影响因子：
14
通讯作者：
Camici, Paolo G.
中科院分区：
文献类型：
--
作者：
Carrio, Ignasi;Cowie, Martin R.;Camici, Paolo G.
间碘苄胍（mIBG）心脏交感神经成像是一种无创性工具，可对心力衰竭（HF）患者进行风险分层。在缺血性和非缺血性心肌病患者中，心脏mIBG活性是一个非常有效的生存预测因子。心脏交感神经成像可以帮助了解交感神经过度活动如何发挥其有害作用，这可能会导致HF患者更好的治疗和结局。（美国科尔心脏病学杂志2010;3：92-100）（C）美国心脏病学会基金会2010年
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF. (J Am Coll Cardiol Img 2010;3:92-100) (C) 2010 by the American College of Cardiology Foundation